Androgenetic alopecia in the
man
Ther Umsch. 2002 May
Bader U, Trueb RM.
Dermatologische Klinik, UniversitatsSpital Zurich.
Androgenetic alopecia (AGA) occurs in approximately 40% of men at the age of 40
and 50% at 50, respectively.
Especially for young men progressive hair loss can
be distressing. Therefore, understanding of these patients' concerns is
important for appropriate management.
Current understanding of the pathophysiology of AGA mainly focuses on androgen metabolism as it affects hair
growth.
As a result, pharmacologic treatment has made considerable progress
through the introduction of selective 5 alpha-reductase inhibition with
finasteride. In placebo-controlled clinical trials in men with AGA, treatment
with oral finasteride proved to be effective.
Minoxidil is the only
pharmacological substance for topical application with proven efficacy. So far,
other treatment modalities have no proven efficacy in clinical trials, so that
their use cannot be recommended.
Options for advanced AGA not amenable to
pharmacologic treatment are autologous hair transplantation and hair
replacement, both of which have recently also made progress in terms of cosmetic
appeal.
|